Recent developments highlight clinical progress in Precision BioSciences’ lead gene editing programs, financial results reflecting ongoing losses, and regulatory advancements including FDA Fast Track designation.

• Precision BioSciences reported Q2 loss and presented clinical data showing elimination of cccDNA in hepatitis B patients with PBGENE-HBV in a global Phase 1/2a trial [N1].
• The company dosed the first patient in the Phase 1/2 trial of PBGENE-DMD for Duchenne muscular dystrophy, targeting exon excision to restore dystrophin protein [N2].
• Precision BioSciences reported Q1 loss but topped revenue estimates, indicating variability in financial performance during clinical development [N2].
• The company surpassed Q4 earnings and revenue estimates in the prior quarter, reflecting operational progress [N5].
• FDA granted Fast Track designation for PBGENE-DMD, supporting regulatory engagement for this program [N5].

The company’s ARCUS platform offers distinct technological advantages that may enable precise and efficient in vivo gene editing therapies. Clinical progress in its lead programs for chronic hepatitis B and Duchenne muscular dystrophy, including regulatory designations such as FDA Fast Track and Orphan Drug status, demonstrate advancement toward potential therapeutic solutions for significant unmet medical needs. Strong liquidity supports ongoing development activities and clinical milestones.

Precision BioSciences has a limited operating history with no commercial products or revenue, and has incurred significant operating losses. The novel nature of its ARCUS technology and gene editing field presents developmental and regulatory uncertainties. The company requires substantial additional funding to continue operations and clinical development. Clinical trials may face delays or fail to demonstrate safety and efficacy. Competitive pressures and evolving regulatory landscapes may impact future prospects.

Precision BioSciences’ moat lies in its proprietary ARCUS genome editing platform, which differentiates itself through a unique staggered DNA cut promoting defined editing outcomes, a smaller size enabling delivery via AAV and LNP vectors, and a single-component design that may improve efficiency and safety. These technological advantages support the development of in vivo gene editing therapies targeting complex genetic diseases. The company’s clinical-stage pipeline and regulatory designations further contribute to its competitive positioning in the emerging gene editing therapeutics field.

• Operating Losses and Capital Requirements: The company has incurred significant operating losses and expects to continue incurring losses for the foreseeable future. It requires substantial additional funding to advance clinical programs and operations.
• Clinical and Regulatory Risks: Development of novel gene editing therapies involves significant uncertainty regarding safety, efficacy, and regulatory approval timelines. Clinical trials may not yield successful results.
• Limited Operating History: The company has a limited operating history and no commercial products, making it difficult to assess future performance and increasing investment risk.
• Dependence on Key Programs and Collaborations: The company’s prospects depend heavily on the success of its lead programs PBGENE-HBV and PBGENE-DMD and collaborations such as with iECURE. Failure in these areas could materially impact the business.
• Market and Competitive Risks: The gene editing field is rapidly evolving with multiple competing technologies and companies. Market acceptance and competitive dynamics may affect the company’s ability to commercialize products.

• Precision BioSciences is a clinical-stage gene editing company utilizing its proprietary ARCUS platform to develop in vivo gene editing therapies targeting genetic and infectious diseases [S1].
• The ARCUS platform is characterized by a unique staggered DNA cut, small size enabling delivery via AAV and LNP, and simplicity as a single-component editor without guide RNA, which may enhance editing efficiency and safety [S1].
• The company’s wholly-owned clinical-stage programs include PBGENE-HBV for chronic hepatitis B aiming to eliminate cccDNA, PBGENE-DMD for Duchenne muscular dystrophy targeting exon excision to restore dystrophin protein, and PBGENE-3243 for mitochondrial disease (paused to prioritize lead programs) [S1].
• PBGENE-HBV is in a global Phase 1/2a trial enrolling patients in multiple countries, designed as a potentially curative treatment by eliminating viral cccDNA and integrated HBV DNA [S1].
• PBGENE-DMD is in a Phase 1/2 trial targeting up to 60% of DMD patients with mutations between exons 45-55, aiming to restore near full-length dystrophin protein; it has received FDA Rare Pediatric Disease, Orphan Drug, and Fast-Track designations [S1].
• The company has partnered programs including iECURE’s ECUR-506 for OTC deficiency, with ongoing clinical trials and FDA RMAT designation [S1].
• Precision BioSciences has collaborations and license agreements with Caribou Biosciences, TG Therapeutics, Imugene, and formerly Novartis (terminated in early 2026) [S1].
• The company has incurred significant operating losses since inception, with a net loss of $58.7 million for the nine months ended September 30, 2026, and an accumulated deficit of $586.9 million as of that date [S2].
• Precision BioSciences has not commercialized any products and has never generated revenue from product sales; its losses are primarily from R&D and general administrative expenses [S2].
• As of September 30, 2026, the company held $81.7 million in cash and equivalents, $0.15 million in short-term investments, current assets of $86.6 million, and current liabilities of $8.27 million, resulting in a current ratio of 10.47 and a cash ratio of 9.9, indicating strong liquidity [S2].
• The company expects its cash runway to fund operating expenses and capital requirements through 2028, including clinical data milestones for PBGENE-HBV and PBGENE-DMD [S2].
• Recent quarterly reports indicate ongoing losses and the need for substantial additional funding to continue development and commercialization efforts [S2].
• Recent news highlights include dosing the first patient in the Phase 1/2 trial of PBGENE-DMD, clinical data showing cccDNA elimination in hepatitis B patients, and receipt of FDA Fast Track status for PBGENE-DMD [N1][N2][N5].
• The company reported Q1 and Q2 losses but topped revenue estimates in Q1 and lagged in Q2, reflecting variability in financial performance during clinical development [N1][N2].
• The company’s stock has experienced volatility with notable price movements and analyst commentary on strength and oversold conditions [N1][N4][N5].